FDA approves Novartis gene therapy Zolgensma for spinal muscular atrophy

The gene therapy will be priced at $2.125 million, or $425,000 per year for five years, under an installment-based payment program for which it is partnered...

Why precision medicines for oncology demands precision engagement

The speed of scientific breakthroughs in precision medicine is leading to groundbreaking treatments, particularly in oncology and rare diseases. More than 85 percent of the oncology...

How a focus on food can move the needle to cost avoidance in healthcare

L to R: moderator Dr. Thomas Hawes, managing director for Sandbox Industries; Rick Born, CEO of Aetna Better Health of Louisiana; Dr. Julia Jenkins, medical director...

Report: Amazon developing emotion-sensing wearable device

Amazon has a health-oriented wearable in the works that has the potential to use voice recognition technology to sense emotional states, according to a report from...

Scott Gottlieb returns to NEA – this time with some valuable regulatory experience under...

One of the largest venture capital firms in the world is adding an enviable member to its healthcare investment team: the man who just stepped down...

MIT researcher, alleged to have copied antibody research Otsuka acquired, evaluating potential legal action

Last year, Japanese drugmaker Otsuka Pharmaceutical paid $430 million to acquire Waltham, Massachusetts-based Visterra, a firm that combines computational and experimental technologies to develop monoclonal antibodies...

Midwestern hospital network launches $100M venture fund

At the inaugural MedCity INVEST Pop Health conference in New Orleans on May 22, West Des Moines, Iowa-based UnityPoint Health announced that it has launched a...

With great data comes great responsibility: New regulatory challenges for health tech

Big data holds commensurately large promise for medtech and digital health companies building tools to analyze that information and develop programs to improve patient health. But these...

CAR-T therapy for kidney cancer shows early signs of efficacy in Chinese trial

A Chinese company has presented early clinical data on two CAR-T therapies in patients with kidney cancer, and it plans to decide by the end of...

Biofourmis raises $35M to support AI-based digital therapeutics for chronic disease

Singaporean startup Biofourmis has raised a $35 million Series B financing round led by to support the growth and commercialization of its digital therapeutics platform and...

Must Read